Regulatory Pierre Fabre’s Braftovi gains CHMP positive opinion for mCRC Pharmaceutical TechnologyThe EMA's CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories' Braftovi to treat mCRC with BRAFV600E mutations.OncologyRead full story pharminent May 26, 2026 (Last updated: May 27, 2026) Pharmaceutical Technology The EMA’s CHMP has issued a positive opinion recommending approval of Pierre Fabre Laboratories’ Braftovi to treat mCRC with BRAFV600E mutations. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: All eyes on Revolution, bispecific antibodies and more at ASCO26Next: Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
